Unlike the findings observed in those dietary/nutrient murine models of NAFLD, the present study suggests that celecoxib directly weakens de novo lipogenesis, which plays a decisive role in Akt‐driven hepatic steatosis, by inhibiting the lipogenic response in an Akt‐dependent manner. Here, AKT1 is linked to metabolic dysfunction-associated steatotic liver disease.